Our Supporters


Amgen Ventures joined Akili’s Series B financing in 2016 as an equity investor.  Amgen Ventures is the strategic ventures capital arm of Amgen and provides emerging innovative companies with financial and other resources to develop pioneering discoveries to treat grievous human illness.  Amgen has a robust product offering and pipeline in oncology, inflammation, and cardiovascular disease.


Canepa Healthcare, LLC joined Akili in both Series A & Series B financing rounds.  Canepa is a late-stage venture and growth capital firm specializing in medical device and diagnostic investing.


Jazz Venture Partners joined Akili’s Series B financing in 2016.  Jazz’s investments focus on partnering with visionary entrepreneurs building companies at the intersection of digital technology and neuroscience.

Merck Ventures joined Akili’s Series B financing in 2016 as an equity investor.  Merck Ventures BV is the strategic, corporate venture capital arm of Merck KGaA, Germany. Merck KGaA is a leading science and technology company for innovative and top-quality high-tech products in healthcare, life sciences and performance materials.  The portfolio includes prescription medications for cancer, multiple sclerosis, and cardiovascular disorders, among many other products.


In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of the Project:EVO™ADHD cognitive measurement product in pediatric ADHD. 

PureTech Health is a founding investor and Akili’s majority shareholder.  With a commitment to developing innovative medicines that have a potentially superior risk-benefit profile over existing treatment options, PureTech Health aims to address some of the largest health issues facing society today.


Our Partners


Autism Speaks, through its not-for-profit investment affiliate DELSIA, entered into a clinical collaboration agreement in early 2015 to support a clinical trial of the proprietary technology platform in children with autism and co-occurring attention deficits. The trial will be a blinded, randomized, placebo-controlled study that will look to measure cognitive and symptom improvement over 1 month of device play. 

Researchers at the Children's Hospital of Philadelphia's Center for Autism Research (CAR) are committed to discovering the causes and mechanisms of autism and driving the development of groundbreaking new interventions to benefit families across the country. CAR's experts also provide direct support for individuals with ASD and their families through evidence-based resources and education. For more information visit CenterforAutismResearch.org and CARautismRoadmap.org


PatientsLikeMe, the world’s largest personalized health network, helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bring the patient voice to research, development and public policy. With more than 600,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies.


Pfizer Pharmaceuticals (PFE) is currently funding a study to validate the ability of the proprietary technology platform to serve as a biomarker or cognitive endpoint for individuals at risk of developing Alzheimer's disease. We believe that this innovative study is the first in which a pharmaceutical company is using a video game to detect a major disease. The study is currently underway.


Researchers at the San Francisco VA Medical Center and UCSF have partnered with Akili to search for interventions that can improve cognitive functioning among older Veterans, particularly those with past traumatic brain injury.

In addition to being the academic home of Akili’s founding scientist, Dr. Adam Gazzaley, the University of California, San Francisco (UCSF) provides a vibrant research community that investigates cognition in many disease areas.  From pediatric behavioral disorders to aging and dementia, researchers at UCSF continue to partner with Akili to evaluate the cognitive benefits of Akili’s technologies.  Akili appreciates all of our collaborators from the Department of Pediatrics, Neuroscape, Bove Lab, and the Memory and Aging Center.


The University of Washington Department of Psychiatry and Behavioral Sciences is conducting a research study to see whether new treatments are effective for depressed, older adults. They are looking for people aged 60 and older who are struggling with mood, depression or low energy. Participants must be able to participate in MRI scans. More information can be found at https://clinicaltrials.gov/ct2/show/NCT02229188